Protective effect of kidney by low dose of darbepoetin alfa in patients with chronic kidney disease
Phase 2
- Conditions
- Chronic kidney disaese
- Registration Number
- JPRN-UMIN000008984
- Lead Sponsor
- Chiba university hospital, Nephrology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Excluded patients with hypertension uncontrolled, congestive heart failure, surgery with massive bleeding within 16 weeks, blood disorders and malignancies, with patients treated with Doosan Mepichiosutan Henin and anabolic hormone and testosterone within 16 weeks, drug allergy, collagen disease and vasculitis, and patients who received a blood transfusion within 16 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method